PDCD1 and cancer: Currently, the two primary immune checkpoint targets in clinical practice are cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and the programmed cell death-1/programmed death-ligand 1 (PD-1/PDL-1) axis, with related antibodies being employed in a range of cancer therapies.